In reaction to disappointing earnings/guidance: FINL -9.7% (light volume), BBRY -5.3%, BGCP -2.7%, NKE -2.6%, NQ -2.6% (also announces proposal to sell FL Mobile to Tack Fiori International Group Limited and become controlling shareholder).
Select pharma stocks trading lower: RHHBY -6% (Immunogen reported that Roche has announced top-line results of its Phase III Marianne study; Roche has reported the Marianne study showed the three regimens helped people live without their disease worsening ), SHPG -1.8%, AZN -1.8%, SNY -1.7%.
Select Euro financial related names showing weakness: BBVA -3.1%, SAN -2.9%, ING -2.6%, DB -1.9%...oil/gas related names: STO -2.3%, TOT -1.7%... telecom names are lower: PT -7% CHA -6.1% (ticking lower), TI -2.2%
Other news: IMGN -39.2% (Immunogen reported that Roche has announced top-line results of its Phase III Marianne study; Roche has reported the Marianne study showed the three regimens helped people live without their disease worsening ), RXII -11.9% (entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals for the therapeutic use of Samcyprone), NVGN -8.4% (entered private placement), GFI -3.6% (still checking), YNDX -2.7% (ongoing Russia related volatility), CRH -2.4% (still checking), NOK -2% (following BBRY results), TNK -1.9% (plans to offer 20,000,000 shares of Class A common stock; downgraded to Neutral from Buy at UBS, tgt raised to $6 from $5.50), BUD -1.9% (still checking), DEO -0.8% (still checking), MET -0.6% (has been designated as systemically importan by regulatorst, as expected), UA -0.5% (following NKE results), .
Analyst comments: SDRL -6.1% (downgraded at Goldman), EVC -1.4% ( downgraded to Neutral from Outperform at Wedbush ), MXIM -0.4% (downgraded to Neutral from Buy at Goldman), WAG -0.2% (downgraded to Neutral from Buy at SunTrust)
.
Select pharma stocks trading lower: RHHBY -6% (Immunogen reported that Roche has announced top-line results of its Phase III Marianne study; Roche has reported the Marianne study showed the three regimens helped people live without their disease worsening ), SHPG -1.8%, AZN -1.8%, SNY -1.7%.
Select Euro financial related names showing weakness: BBVA -3.1%, SAN -2.9%, ING -2.6%, DB -1.9%...oil/gas related names: STO -2.3%, TOT -1.7%... telecom names are lower: PT -7% CHA -6.1% (ticking lower), TI -2.2%
Other news: IMGN -39.2% (Immunogen reported that Roche has announced top-line results of its Phase III Marianne study; Roche has reported the Marianne study showed the three regimens helped people live without their disease worsening ), RXII -11.9% (entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals for the therapeutic use of Samcyprone), NVGN -8.4% (entered private placement), GFI -3.6% (still checking), YNDX -2.7% (ongoing Russia related volatility), CRH -2.4% (still checking), NOK -2% (following BBRY results), TNK -1.9% (plans to offer 20,000,000 shares of Class A common stock; downgraded to Neutral from Buy at UBS, tgt raised to $6 from $5.50), BUD -1.9% (still checking), DEO -0.8% (still checking), MET -0.6% (has been designated as systemically importan by regulatorst, as expected), UA -0.5% (following NKE results), .
Analyst comments: SDRL -6.1% (downgraded at Goldman), EVC -1.4% ( downgraded to Neutral from Outperform at Wedbush ), MXIM -0.4% (downgraded to Neutral from Buy at Goldman), WAG -0.2% (downgraded to Neutral from Buy at SunTrust)
.